4.3 Article

Association Between 30-Day Episode Payments and Acute Myocardial Infarction Outcomes Among Medicare Beneficiaries

Journal

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCOUTCOMES.117.004397

Keywords

health expenditures; Medicare; mortality; myocardial infarction; percutaneous coronary intervention

Funding

  1. National Institutes of Health Training Grant, Brigham and Women's Hospital, Division of Cardiovascular Medicine [T32HL007604-32]
  2. National Heart, Lung, and Blood Institute [K23HL109177-03]
  3. Amarin
  4. Amgen
  5. AstraZeneca
  6. Bristol-Myers Squibb
  7. Chiesi
  8. Eisai
  9. Ethicon
  10. Forest Laboratories
  11. Ironwood
  12. Ischemix
  13. Lilly
  14. Medtronic
  15. Pfizer
  16. Roche
  17. Sanofi Aventis
  18. The Medicines Company
  19. National Heart, Lung and Blood Institute [R01HL136708]
  20. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology
  21. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL136708, T32HL007604, K23HL118138, K23HL109177] Funding Source: NIH RePORTER

Ask authors/readers for more resources

BACKGROUND: Recent policy efforts have focused on improving the value of acute myocardial infarction (AMI) care. Medicare payment programs, for example, increasingly evaluate hospital performance based on spending, as determined by payments made to institutions and providers, and outcome measures for a longitudinal episode of AMI care. Little is known about the relationship between total 30-day payments-both in the inpatient and immediate postdischarge timeframe-and outcomes after an admission for AMI. METHODS AND RESULTS: Using Medicare claims data, we identified Medicare fee-for-service beneficiaries >= 65 years of age who were hospitalized at an acute-care hospital for AMI between July 1, 2011, and June 30, 2014, and examined the association between hospital-level 30-day payments for an episode of AMI care and patient 30-day mortality using mixed regression models with a logit link function and random hospital intercepts. Our cohort included 642 105 index hospitalizations for AMI at 2319 acute-care hospitals. Overall mean 30-day episode payments per beneficiary were $22 128 (SD, $1750). The observed 30-day mortality rate was 12.9%. Higher 30-day payments were associated with lower 30-day mortality after adjustment for patient characteristics and comorbidities (adjusted odds ratio for additional $1000 payments, 0.986; 95% confidence interval, 0.979-0.992; P<0.001). Additional adjustment for potential mediating factors, including hospital characteristics, coronary revascularization rates, and discharge disposition, did not significantly attenuate the relationship (adjusted odds ratio for additional $1000 payments, 0.987; 95% confidence interval, 0.980-0.994; P<0.001). CONCLUSIONS: Higher hospital-level 30-day payments-both inpatient and in multiple settings after discharge-for AMI care were associated with lower 30-day mortality among beneficiaries. This may have implications for payment programs that incent reduction in payments without considering value.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available